Zhejiang Huahai Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Zhejiang Huahai Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Zhejiang Huahai Pharmaceutical Co Ltd Strategy Report
- Understand Zhejiang Huahai Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Zhejiang Huahai Pharmaceutical Co Ltd (Huahai Pharmaceuticals) discovers, carries out the research, production and sale of formulations, active pharmaceutical ingredients (APIs) including ace inhibitors, angiotensin II receptor antagonists, anti-AIDS, anti-depressants, antihistamines, antihypertensives, and antipsychotics, and pharmaceutical intermediates. It also carries out the commercial production of captopril, enalapril and lisinopril. The company has two reportable segments, Main Business and Other Business. In Main Business, the company reports the performance of its Raw Material and Intermediaries; Finished Drugs; Technical Services; Import and Export and Others. The company operates through subsidiaries in the US and China and distributes its products to several countries worldwide. Huahai Pharmaceuticals is headquartered in Zhejiang, China.
Headquarters
China
Address
Xunqiao, Linhai City, Taizhou, Zhejiang, 317024
Website
www.huahaipharm.com
Telephone
86 576 85991096
No of Employees
7,682
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600521 (SHA)
Revenue (2021)
$1.2B
24.4%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
139.5%
(2021 vs 2020)
Market Cap*
$3.1B
Net Profit Margin (2021)
XYZ
92.5%
(2021 vs 2020)
* As of and is in US$
Zhejiang Huahai Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Active Pharmaceutical Ingredients | Technology Services |
| Pharmaceutical Intermediates | |
| Formulations: | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Zhejiang Huahai Pharmaceutical Co Ltd | Shanghai Pharmaceuticals Holding Co Ltd | China National Accord Medicines Corporation Ltd | Nanjing Pharmaceutical Co Ltd | Jiangsu Hengrui Medicine Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Taizhou | Shanghai | Shenzhen | Nanjing | Lianyungang |
| State/Province | Zhejiang | Shanghai | Guangdong | Jiangsu | Jiangsu |
| No. of Employees | 7,682 | 48,164 | 39,296 | 5,058 | 20,636 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mei Zhang | Director - Finance; Chief Financial Officer | Senior Management | 2008 | 46 |
| Li Hong | Chairman | Executive Board | 2019 | 61 |
| Baohua Chen | President; General Manager; Director | Executive Board | 2013 | - |
| Zhu Yonghua | Secretary; Director | Executive Board | 2009 | - |
| Qimao Chen | Vice President | Senior Management | 2019 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward